# A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity

> **NCT06862908** · PHASE2 · RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 141 (estimated)

## Conditions studied

- Obesity
- Heart Failure With Preserved Ejection Fraction (HFPEF)
- Heart Failure With Mildly Reduced Ejection Fraction

## Interventions

- **OTHER:** placebo
- **DRUG:** IBI362

## Key facts

- **NCT ID:** NCT06862908
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2026-09-24
- **Final completion:** 2027-02-11
- **Target enrollment:** 141 (ESTIMATED)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06862908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06862908, "A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06862908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*